Aptamer-based nanoparticle drug delivery system designed for targeting GPC3-positive liver cancer

Hongxin Zhou; Shuangshuang Dong; Zhan Si; Hao Niu; Jianwen Mao; Yiran Chen; Yuhuan Li; Weizhong Wu

doi:10.1016/j.jpha.2026.101614

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2026 > Accepted Manu

Hongxin Zhou, Shuangshuang Dong, Zhan Si, Hao Niu, Jianwen Mao, Yiran Chen, Yuhuan Li, Weizhong Wu. Aptamer-based nanoparticle drug delivery system designed for targeting GPC3-positive liver cancer[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2026.101614

Citation:

Hongxin Zhou, Shuangshuang Dong, Zhan Si, Hao Niu, Jianwen Mao, Yiran Chen, Yuhuan Li, Weizhong Wu. Aptamer-based nanoparticle drug delivery system designed for targeting GPC3-positive liver cancer[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2026.101614

Citation:

Hongxin Zhou, Shuangshuang Dong, Zhan Si, Hao Niu, Jianwen Mao, Yiran Chen, Yuhuan Li, Weizhong Wu. Aptamer-based nanoparticle drug delivery system designed for targeting GPC3-positive liver cancer[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2026.101614

PDF( 0 KB)

Aptamer-based nanoparticle drug delivery system designed for targeting GPC3-positive liver cancer

doi: 10.1016/j.jpha.2026.101614

a. Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, 200032, China;
b. Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, China

Funds:

This study was funded by the National Natural Science Foundation of China (Grant No.: 82073216) and Projection of Shanghai Science and Technology Committee, China (Grant No.: 20S11906300).

Received Date: Mar. 10, 2025
Accepted Date: Mar. 24, 2026
Rev Recd Date: Mar. 23, 2026
Available Online: Mar. 25, 2026

Abstract

Abstract

Nucleic acid aptamers, short single-stranded DNA (ssDNA) or RNA molecules generated via systematic evolution of ligands by exponential enrichment (SELEX), have emerged as promising alternatives to traditional antibodies owing to their exceptional specificity and affinity. These unique properties render them invaluable tools in both scientific research and clinical theranostics. In recent years, aptamer-functionalized nanomaterials have demonstrated substantial potential as tumor-targeted drug delivery systems, offering notable advantages such as reduced systemic toxicity and enhanced therapeutic efficacy. In this study, we developed a novel targeted drug delivery system specifically designed for glypican-3 (GPC3)-positive hepatocellular carcinoma (HCC) by conjugating the GPC3-targeted aptamer AP613-1 to liposomes encapsulating doxorubicin (DOX). To enhance the biostability and binding affinity of the aptamer, we constructed an aptamer-embedded triangular nanostructure (mTriangle-AP613-1) using a DNA origami technique. Characterization results revealed that the mTriangle-AP613-1 nanostructure exhibited a significantly improved dissociation constant (K_D) of 15.2 ± 0.21 nM and enhanced biosafety profiles compared to free aptamers. Both in vitro and in vivo evaluations demonstrated that DOX-loaded mTriangle-AP613-1-liposomes achieved superior tumor growth inhibition in GPC3-positive tumor models compared to control groups. These findings highlight the potential of mTriangle-AP613-1-liposomes (DOX) as a highly effective nanomedicine platform for targeted cancer therapy. Notably, our results underscore the translational value of aptamer-functionalized nanostructures in advancing precision oncology through optimized drug delivery systems.
- Nucleic acid aptamers,
- Glypican-3,
- Doxorubicin,
- DNA origami,
- Drug delivery system

FullText(HTML)

References(18)

References

[1]	Y. Wang, B. Deng, Hepatocellular carcinoma: Molecular mechanism, targeted therapy, and biomarkers, Cancer Metastasis Rev. 42 (2023) 629-652.
[2]	F. Zhou, W. Shang, X. Yu, et al., Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment, Med. Res. Rev. 38 (2018) 741-767.
[3]	E. J. Schepers, K. Glaser, H.M. Zwolshen, et al., Structural and functional impact of posttranslational modification of glypican-3 on liver carcinogenesis, Cancer Res. 83 (2023) 1933-1940.
[4]	C. Tuerk, L. Gold, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase, Science 249 (1990) 505-510.
[5]	A.D. Ellington, J.W. Szostak, In vitro selection of RNA molecules that bind specific ligands, Nature 346 (1990) 818-822.
[6]	J. Zhou, J. Rossi, Aptamers as targeted therapeutics: Current potential and challenges, Nat. Rev. Drug Discov. 16 (2017), 440.
[7]	B.B. Mendes, J. Conniot, A. Avital, et al., Nanodelivery of nucleic acids, Nat. Rev. Methods. Primers 2 (2022).
[8]	P.W.K. Rothemund, Folding DNA to create nanoscale shapes and patterns, Nature 440 (2006) 297-302.
[9]	D Han, X Qi, C. Myhrvold, et al., Single-stranded DNA and RNA origami, Science 358 (2017), eaao2648.
[10]	X. Qi, F. Zhang, Z. Su, et al., Programming molecular topologies from single-stranded nucleic acids, Nat. Commun. 9 (2018), 4579.
[11]	F. Praetorius, B. Kick, K.L. Behler, et al., Biotechnological mass production of DNA origami, Nature 552 (2017) 84-87.
[12]	L. Dong, H. Zhou, M. Zhao, et al., Phosphorothioate-modified AP613-1 specifically targets GPC3 when used for hepatocellular carcinoma cell imaging, Mol. Ther. Nucleic Acids 13 (2018) 376-386.
[13]	H. Gu, K. Furukawa, Z. Weinberg, et al., Small, highly active DNAs that hydrolyze DNA, J. Am. Chem. Soc. 135 (2013) 9121-9129.
[14]	Y. Yang, Z. Wu, L. Wang, et al., Sorting sub-150-nm liposomes of distinct sizes by DNA-brick-assisted centrifugation, Nat. Chem. 13 (2021) 335-342.
[15]	Y. Jia, L. Chen, J. Liu, et al., DNA-catalyzed efficient production of single-stranded DNA nanostructures, Chem 7 (2021) 959-981.
[16]	Y. Zhang, Y. Xiong, Y. Xiao, 3dDNA: A computational method of building DNA 3D structures, Molecules 27 (2022), 5936.
[17]	B.G. Pierce, K. Wiehe, H. Hwang, et al., ZDOCK server: Interactive docking prediction of protein-protein complexes and symmetric multimers, Bioinformatics 30 (2014) 1771-1773.
[18]	P. Tardi, N. Boman, P. Cullis, Liposomal doxorubicin, J. Drug Target. 4 (1996) 129-140.